{"id":"act-709478-for-oral-use","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ACT-709478 works by blocking the action of dopamine at D2/D3 receptors in the brain, which may help to reduce symptoms of psychiatric disorders such as schizophrenia and major depressive disorder.","oneSentence":"ACT-709478 is a selective dopamine receptor D2/D3 antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:18:52.582Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant schizophrenia"},{"name":"Major depressive disorder"}]},"trialDetails":[{"nctId":"NCT03165097","phase":"PHASE1","title":"Study to Evaluate Safety and Tolerability of ACT-709478 in Healthy Subjects","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-07-07","conditions":"Healthy Subjects","enrollment":46},{"nctId":"NCT03239691","phase":"PHASE2","title":"A Study to Evaluate the Effect of ACT-709478 in Photosensitive Epilepsy Patients","status":"COMPLETED","sponsor":"Idorsia Pharmaceuticals Ltd.","startDate":"2017-10-06","conditions":"Photosensitive Epilepsy","enrollment":5}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ACT-709478 for oral use","genericName":"ACT-709478 for oral use","companyName":"Idorsia Pharmaceuticals Ltd.","companyId":"idorsia-pharmaceuticals-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ACT-709478 is a selective dopamine receptor D2/D3 antagonist. Used for Treatment-resistant schizophrenia, Major depressive disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}